ASH 2023 | An update on olverembatinib in patients with R/R CML and Ph+ ALL
Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses olverembatinib – a novel, potent BCR:ABL1 tyrosine kinase inhibitor (TKI), which was studied as monotherapy or in combination with blinatumomab in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) (NCT04260022). The study showed that olverembatinib administered as monotherapy or in combination was well tolerated and efficacious in heavily pre-treated patients with CML or Ph+ ALL who were either resistant or intolerant to ponatinib and/or asciminib. Dr Jabbour hopes this agent will provide a therapeutic option to patients who have failed several prior lines of therapy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Ascentage Pharma Group, Hikma Pharmaceuticals, Genentech, Pfizer, Amgen, Adaptive Biotech, Takeda, Novartis, Bristol-Myers Squibb, Abbvie
Honoraria: Ascentage Pharma Group, Hikma Pharmaceuticals, Genentech, Pfizer, Amgen, Adaptive Biotech, Takeda, Astex, Bristol-Myers Squibb, Abbvie
Research Funding: Ascentage Pharma Group, Hikma Pharmaceuticals, Genentech, Pfizer, Amgen, Adaptive Biotech, Takeda, Novartis, Astex, Bristol-Myers Squibb, Abbvie
